SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases

Bibliography

• Burns A, Iliffe S. Alzheimer's disease. BMJ 2009;338:b158
   PubMed Web of Science ®Google Scholar
• Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 1992;55:1106-15
   PubMed Web of Science ®Google Scholar
• Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007;68:1002-7
   PubMed Web of Science ®Google Scholar
• Azbill RD, Mu X, Springer JE. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 2000;871:175-80
   PubMed Web of Science ®Google Scholar
• Dunlop J, Beal McIlvain H, She Y, Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003;23:1688-96
   PubMed Web of Science ®Google Scholar
• Gent P, Massey K. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin. Int J Palliat Nurs 2001;7:354-9
   PubMedGoogle Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009;145:3-14
   PubMed Web of Science ®Google Scholar
• Hefti F, Will B. Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons; implications for alzheimer's disease. J Neural Transm Suppl 1987;24:309-15
   PubMedGoogle Scholar
• Bennet MR, Gibson WG, Lemon G. Neuronal cell death, nerve growth factor and neurotrophic models: 50 years on. Auton Neurosci 2002;95:1-23
   PubMed Web of Science ®Google Scholar
• Hyman C, Hofer M, Barde YA, BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350:230-2
   PubMed Web of Science ®Google Scholar
• Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003;72:609-42
   PubMed Web of Science ®Google Scholar
• Eriksdotter Jönhagen M, Nordberg A, Amberla K, Intracerebroventricular infusion of nerve growth factor in three patients with alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:246-57
   PubMed Web of Science ®Google Scholar
• Meininger V, Bensimon G, Bradley WR, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:107-17
   PubMed Web of Science ®Google Scholar
• Bachy A, Steinberg R, Santucci V, Biochemical and electrophysiological properties of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundam Clin Pharmacol 1993;7:487-97
   PubMed Web of Science ®Google Scholar
• Cervo L, Bendotti C, Tarizzo G, Potential antidepressant properties of SR 57746A, a novel compound with selectivity and high affinity for 5-HT1A receptors. Eur J Pharmacol 1994;253:139-47
   PubMed Web of Science ®Google Scholar
• Lanfumey L, Hamon M. 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:1-10
   PubMedGoogle Scholar
• Hall H, Lundkvist C, Halldin C, Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res 1997;745:96-108
   PubMed Web of Science ®Google Scholar
• Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007;59:360-417
   PubMed Web of Science ®Google Scholar
• Hajos M, Gartside SE, Varga V, In vivo inhibition of neuronal activity in the rat ventromedial prefrontal cortex by midbrain-raphe nuclei: role of 5-HT1A receptors. Neuropharmacology 2003;45:72-81
   PubMed Web of Science ®Google Scholar
• Lopez JF, Chalmers DT, Little KY, AE Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998;43:547-73
   PubMed Web of Science ®Google Scholar
• Lanzenberger RR, Mitterhauser M, Spindelegger C, Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007;61:1081-9
   PubMed Web of Science ®Google Scholar
• King MV, Marsden CA, Fone KC. A role for the 5-HT(1A), 5-HT(4) and 5-HT(6) receptors in learning and memory. Trends Pharmacol Sci 2008;29(9):482-92
   PubMed Web of Science ®Google Scholar
• Labie C, Lafon C, Marmouget C, Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. Br J Pharmacol 1999;127:139-44
   PubMed Web of Science ®Google Scholar
• Apfel SC, Wright DE, Wiideman AM, Nerve growth factor regulates the expression of brain-derived neurotrophic factor mRNA in the peripheral nervous system. Mol Cell Neurosci 1996;7:134-42
   PubMed Web of Science ®Google Scholar
• Fournier J, Keane PE, Ferrara P, SR 57746A: an orally active non-peptidecompound with neurotrophic and neuroprotective effects. CNS Drug Rev 1997;3:148-67
   Google Scholar
• Duong FH, Warter JM, Poindron P, Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons. Br J Pharmacol 1999;128:1385-92
   PubMed Web of Science ®Google Scholar
• Appert-Collin A, Duong FH, Passilly DeGrace P, Xaliproden (SR57746A) induces 5-HT1A receptor-mediated MAP kinase activation in PC12 cells. Int J Immunopathol Pharmacol 2005;18:233-44
   PubMed Web of Science ®Google Scholar
• Pradines A, Magazin M, Schiltz P, Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem 1995;64:1954-64
   PubMed Web of Science ®Google Scholar
• Paves H, Neuman T, Metsis M, Nerve growth factor induces rapid redistribution of F-actin in PC12 cells. FEBS Lett 1988;235:141-3
   PubMed Web of Science ®Google Scholar
• Fournier J, Boutot G, Keane PE, The non-peptide neuroprotective agents SR 57746A interacts with neurotrophin 3 to induce differentiation in the PC12 cell-line. J Pharm Pharmacol 1998;50:323-7
   PubMed Web of Science ®Google Scholar
• Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004;26:870-81
   PubMed Web of Science ®Google Scholar
• Tigyi G, Fischer DJ, Sebok A, Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and rho. J Neurochem 1996;66:537-48
   PubMed Web of Science ®Google Scholar
• Ye X, Ishii I, Kingsbury MA, Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim Biophys Acta 2002;1585:108-13
   PubMed Web of Science ®Google Scholar
• Magazin M, Schiltz P, Zachayus JL, Inhibition of lysophosphatidic acid-induced neurite retraction and cell rounding by SR 57746A. Brain Res Mol Brain Res 1998;53:301-6
   PubMedGoogle Scholar
• Labie C, Canolle B, Chatelin S, Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis. Curr Alzheimer Res 2006;3:35-6
   PubMedGoogle Scholar
• Ruigt GS, Makkink WK, Konings PN. SR 57746A attenuates cytostatic drug-induced reduction of neurite outgrowth in co-cultures of rat dorsal root ganglia and schwann cells. Neurosci Lett 1996;203:9-12
   PubMed Web of Science ®Google Scholar
• Simiand J, Keane PE, Barnouin MC, Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundam Clin Pharmacol 1993;7:413-27
   PubMed Web of Science ®Google Scholar
• Fournier J, Steinberg R, Gauthier T, Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 1993;55:629-41
   PubMed Web of Science ®Google Scholar
• Lemaire L, Fournier J, Ponthus C, Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats. Invest Radiol 2002;37:321-7
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Shiojima T, Kinoshita M, SR57746A: a survival factor for motor neurons in vivo. J Neurol Sci 1998;160(Suppl 1):S92-6
   PubMed Web of Science ®Google Scholar
• Bourrie B, Bribes E, Esclangon M, The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. Proc Natl Acad Sci USA 1999;96:12855-9
   PubMed Web of Science ®Google Scholar
• Schmalbruch H, Jensen HJ, Bjaerg M, A new mouse mutant with progressive motor neuronopathy. J Neuropathol Exp Neurol 1991;50:192-204
   PubMed Web of Science ®Google Scholar
• Duong F, Fournier J, Keane PE, The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouse. Br J Pharmacol 1998;124:811-7
   PubMed Web of Science ®Google Scholar
• Appert-Collin A, Duong FH, Passilly-Degrace P, Quantification of neurotrophin mRNA expression in PMN mouse: modulation by xaliproden. Int J Immunopathol Pharmacol 2004;17:157-64
   PubMed Web of Science ®Google Scholar
• Lue LF, Kuo YM, Roher AE, Soluble amyloid beta peptide concentration as a predictor of synaptic change in alzheimer's disease. Am J Pathol 1999;155:853-62
   PubMed Web of Science ®Google Scholar
• Terranova JP, Kan JP, Storme JJ, Administration of amyloid beta-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound. Neurosci Lett 1996;213:79-82
   PubMed Web of Science ®Google Scholar
• Croci T, Landi M, Bianchetti A, Drug-induced defaecation in rats: role of central 5-HT1A receptors. Br J Pharmacol 1995;115:203-9
   PubMed Web of Science ®Google Scholar
• Available from: http://en.sanofi-aventis.com/press/press_releases/2007/ ppc_15321.asp
   Google Scholar
• Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005;5(Suppl 1):S38-46
   PubMedGoogle Scholar
• Gibson TB, Ranganathan A, D'Orazio A. Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006. Clin Colorectal Cancer 2006;5:398-402
   PubMedGoogle Scholar
• Wolf S, Barton D, Kottschade L, Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507-15
   PubMed Web of Science ®Google Scholar